Clinical Trial Update: Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of ARCT-032 to assess safety, tolerability, and efficacy in people with cystic fibrosis; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ARCT-032

Snippet

Sponsor: Arcturus Therapeutics, Inc. | Conditions: Cystic Fibrosis, CFTR Gene Mutation | Phase 2 | Status: RECRUITING